(MENAFN- GetNews) Keratoconus Pipeline Insight, 2020″ report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Keratoconus market. A detailed picture of the Keratoconus pipeline landscape is provided, which includes the disease overview and Keratoconus treatment guidelines.
Keratoconus is an eye disorder characterized by progressive thinning and changes in the shape of the cornea.
The pipeline of KC possess only one key player, which is iVeena Delivery Systems. The dynamics of KC market is anticipated to change in the coming years owing to the improvement in the research and development activities so that market will comprise of efficient treatment options. The launch of emerging therapy is expected during the forecast period of 2020-2030.
IVMED-80 is the first twice-daily, eye-drop, non-surgical, non-UV light treatment for medical crosslinking of the cornea being developed by iVeena Delivery Systems. The drug, with its copper-based formulation, is reportedly the first eye drop designed to treat KC without the need for adjunctive laser treatment or surgical intervention. IVMED-80's mechanism of action centers on enhancing the activity of lysyl oxidase (LOX) the enzyme responsible for corneal collagen crosslinking, and also known to be associated with KC and copper, which is a co-factor of LOX, is the active ingredient of the drug. The FDA granted orphan drug designation for IVMED-80 for the treatment of KC. In February 2019, the company announced the commencement of a 36 patient phase I/IIa pilot clinical study for the treatment of mild and moderate KC (IVMED-80) and presented an abstract of the trial in the 2020 ARVO Annual Meeting. Final results of the trial are expected at the end of August 2020. Currently, this therapy is in phase I/II a clinical developmental trial for mild and moderate form of KC.
Keratoconus Marketed therapies
Photrexa Viscous and Photrexa: Glaukos/Avedro CE Marked Riboflavin Formulations: Avedro/ Glaukos Corporation Ricrolin: Sooft Italia Collagex Riboflavin: Lightmed_OptiMed Peschke Riboflavin Solutions: Peschke Meditrade GmbH Keratoconus Emerging Therapies
IVMED-80: iVeena Delivery Systems
Request for sample pages
Table of contents
1. Report Introduction
2. Keratoconus
2.1. Overview
2.2. History
2.3. Keratoconus Symptoms
2.4. Causes
2.5.Pathophysiology
2.6. Keratoconus Diagnosis
2.6.1. Diagnostic Guidelines
3. Keratoconus Current Treatment Patterns
3.1. Keratoconus Treatment Guidelines
4. Keratoconus - DelveInsight's Analytical Perspective
4.1. In-depth Commercial Assessment
4.1.1. Keratoconus companies collaborations, Licensing, Acquisition -Deal Value Trends
4.1.1.1. Assessment Summary
4.1.2. Keratoconus Collaboration Deals
4.1.2.1. Company-Company Collaborations (Licensing / Partnering) Analysis
4.1.2.2. Company-University Collaborations (Licensing / Partnering) Analysis
4.1.2.3. Keratoconus Acquisition Analysis
5. Therapeutic Assessment
5.1. Clinical Assessment of Pipeline Drugs
5.1.1. Assessment by Phase of Development
5.1.2. Assessment by Product Type (Mono / Combination)
5.1.2.1. Assessment by Stage and Product Type
5.1.3. Assessment by Route of Administration
5.1.3.1. Assessment by Stage and Route of Administration
5.1.4. Assessment by Molecule Type
5.1.4.1. Assessment by Stage and Molecule Type
5.1.5. Assessment by MOA
5.1.5.1. Assessment by Stage and MOA
5.1.6. Assessment by Target
5.1.6.1. Assessment by Stage and Target
6. Keratoconus Late Stage Products (Phase-III)
7. Keratoconus Mid Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Keratoconus Discontinued Products
13. Keratoconus Product Profiles
13.1. Drug Name: Company
13.1.1. Product Description
13.1.1.1. Product Overview
13.1.1.2. Mechanism of action
13.1.2. Research and Development
13.1.2.1. Clinical Studies
13.1.3. Product Development Activities
13.1.3.1. Collaboration
13.1.3.2. Agreements
13.1.3.3. Acquisition
13.1.3.4. Patent Detail
13.1.4. Tabulated Product Summary
13.1.4.1. General Description Table
14. Keratoconus Key Companies
15. Keratoconus Key Products
16. Dormant and Discontinued Products
16.1. Dormant Products
16.1.1. Reasons for being dormant
16.2. Discontinued Products
16.2.1. Reasons for the discontinuation
17. Keratoconus Unmet Needs
18. Keratoconus Future Perspectives
19. Keratoconus Analyst Review
20. Appendix
21. Report Methodology
Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States
Website: [To enable links contact MENAFN]
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.